TWD 81.8
(-1.09%)
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2023 | 6.52 Million TWD | -88.88% |
2022 | 58.66 Million TWD | 947.96% |
2021 | 5.59 Million TWD | -77.04% |
2020 | 24.37 Million TWD | 6928.29% |
2019 | -357 Thousand TWD | 0.0% |
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2024 Q1 | 8.09 Million TWD | 984.15% |
2024 Q2 | 8.09 Million TWD | 0.0% |
2023 Q2 | 4.17 Million TWD | 0.0% |
2023 Q4 | -915 Thousand TWD | 0.0% |
2023 Q1 | 4.17 Million TWD | -67.3% |
2023 FY | 6.52 Million TWD | -88.88% |
2023 Q3 | -915 Thousand TWD | -121.91% |
2022 Q3 | 12.77 Million TWD | 0.0% |
2022 FY | 58.66 Million TWD | 947.96% |
2022 Q4 | 12.77 Million TWD | 0.0% |
2021 FY | 5.59 Million TWD | -77.04% |
2020 FY | 24.37 Million TWD | 6928.29% |
2019 FY | -357 Thousand TWD | 0.0% |
Name | Gross Profit | Gross Profit Difference |
---|---|---|
BIONET Corp. | 638.27 Million TWD | 98.978% |
DIVA Laboratories, Ltd. | 250.77 Million TWD | 97.399% |
Genetics Generation Advancement Corp. | 236.83 Million TWD | 97.246% |
Welgene Biotech Co.,Ltd. | 119.71 Million TWD | 94.551% |
TFBS Bioscience Inc. | 77.82 Million TWD | 91.619% |